[{"from": "human", "value": "Describe this molecule. [C][C@H1][C][C@@H1][Branch2][=Branch1][Ring1][C@@H1][Branch2][Branch1][=C][C@H1][Branch2][Branch1][=Branch2][/C][=C][Branch2][Branch1][Ring1][/C@@H1][Branch2][Ring2][=Branch2][C@H1][Branch2][Ring2][Ring1][/C][=C][\\C][=C][Branch2][Ring1][O][\\C][=Branch1][C][=O][N][C][=C][C][=Branch1][C][=O][C][=Branch1][N][=C][Branch1][Branch1][C][Ring2][Ring1][#Branch1][C][Ring1][Branch2][=O][N][/C][O][C][O][C][=Branch1][C][=O][N][\\C][C][O][O][C]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable formulation of the ansamycin derivative 17-amino-17-demethoxygeldanamycin (17-AG) with potential antineoplastic activity. Oral Hsp90 inhibitor IPI-493 binds to and inhibits Hsp90, which may result the in growth inhibition in sensitive tumor cell populations. Hsp90, a 90 kDa molecular chaperone, may be highly expressed in tumor cells, playing a key role in the conformational maturation, stability and function of other substrate or \"client\" proteins within the cell; many of these client proteins are involved in signal transduction, cell cycle regulation and apoptosis, and may include kinases, transcription factors and hormone receptors."}]